Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells $366,462.51 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) Director Michael A. Zasloff sold 10,291 shares of Amphastar Pharmaceuticals stock in a transaction on Monday, May 16th. The shares were sold at an average price of $35.61, for a total transaction of $366,462.51. Following the completion of the transaction, the director now owns 47,206 shares in the company, valued at $1,681,005.66. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

NASDAQ:AMPH opened at $35.93 on Wednesday. The company has a market capitalization of $1.75 billion, a PE ratio of 22.32 and a beta of 0.66. The company has a quick ratio of 2.35, a current ratio of 3.19 and a debt-to-equity ratio of 0.16. Amphastar Pharmaceuticals, Inc. has a 52-week low of $17.56 and a 52-week high of $44.46. The stock has a fifty day simple moving average of $36.38 and a 200-day simple moving average of $28.11.

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Rating) last released its quarterly earnings results on Tuesday, May 10th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.11. Amphastar Pharmaceuticals had a return on equity of 17.35% and a net margin of 17.87%. During the same quarter in the prior year, the firm posted $0.27 earnings per share. As a group, equities analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 1.58 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the stock. First Quadrant L P CA acquired a new position in Amphastar Pharmaceuticals in the 4th quarter valued at about $36,000. Allworth Financial LP acquired a new position in shares of Amphastar Pharmaceuticals during the 4th quarter valued at about $42,000. Lazard Asset Management LLC acquired a new position in shares of Amphastar Pharmaceuticals during the 4th quarter valued at about $42,000. Advisor Group Holdings Inc. increased its stake in shares of Amphastar Pharmaceuticals by 314.2% during the 4th quarter. Advisor Group Holdings Inc. now owns 2,311 shares of the company’s stock valued at $54,000 after acquiring an additional 1,753 shares during the last quarter. Finally, Royal Bank of Canada grew its holdings in shares of Amphastar Pharmaceuticals by 253.4% during the 2nd quarter. Royal Bank of Canada now owns 3,534 shares of the company’s stock worth $71,000 after purchasing an additional 2,534 shares during the period. 59.79% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts recently weighed in on the stock. Wells Fargo & Company lifted their price objective on shares of Amphastar Pharmaceuticals from $23.00 to $32.00 and gave the company an “equal weight” rating in a research report on Tuesday, March 15th. Zacks Investment Research lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Northland Securities lifted their price target on Amphastar Pharmaceuticals from $33.00 to $43.00 in a research note on Monday, April 11th. Piper Sandler lifted their price target on Amphastar Pharmaceuticals from $28.00 to $35.00 and gave the stock an “overweight” rating in a research note on Friday, March 11th. Finally, StockNews.com initiated coverage on Amphastar Pharmaceuticals in a research note on Thursday, March 31st. They set a “buy” rating for the company. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $37.25.

About Amphastar Pharmaceuticals (Get Rating)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API.

Read More